A p53 Drug Response Signature Identifies Prognostic Genes in High-Risk Neuroblastoma

• Eveline Barbieri,

  Affiliation Texas Children’s Cancer Center and Center for Cell and Gene Therapy, Department of Pediatrics, Baylor College of Medicine, Houston, Texas, United States of America

  ⨯
• Katleen De Preter,

  Affiliation Center for Medical Genetics, Ghent University, Ghent, Belgium

  ⨯
• Mario Capasso,

  Affiliation CEINGE Biotecnologie Avanzate, Department of Biochemistry and Medical Biotechnology, University of Naples Federico II, Naples, Italy

  ⨯
• Peter Johansson,

  Affiliation Oncogenomics Section, Pediatric Oncology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, United States of America

  ⨯
• Tsz-Kwong Man,

  Affiliation Texas Children’s Cancer Center and Center for Cell and Gene Therapy, Department of Pediatrics, Baylor College of Medicine, Houston, Texas, United States of America

  ⨯
• Zaowen Chen,

  Affiliation Texas Children’s Cancer Center and Center for Cell and Gene Therapy, Department of Pediatrics, Baylor College of Medicine, Houston, Texas, United States of America

  ⨯
• Paris Stowers,

  Affiliation Texas Children’s Cancer Center and Center for Cell and Gene Therapy, Department of Pediatrics, Baylor College of Medicine, Houston, Texas, United States of America

  ⨯
• Gian Paolo Tonini,

  Affiliation Pediatric Research Institute, University of Padua, Padua, Italy

  ⨯
• Frank Speleman,

  Affiliation Center for Medical Genetics, Ghent University, Ghent, Belgium

  ⨯
• Jason M. Shohet

  * E-mail: jmshohet@txch.org

  Affiliation Texas Children’s Cancer Center and Center for Cell and Gene Therapy, Department of Pediatrics, Baylor College of Medicine, Houston, Texas, United States of America

  ⨯